EV Therapeutics

EV Therapeutics is developing novel therapies to induce an anti-tumor immune response in advanced stage metastatic colorectal cancers. Our technology is based on our proprietary modified extracellular vesicles (mEVs) that significantly enhance tumor antigen-specific T cell infiltration into the tumor microenvironment and synergizes with current immune checkpoint blockade therapies. Mechanistically, our therapeutic platform activates tumor-specific T cell costimulation. Our extensive pre-clinical data show that treatment with mEVs significantly improves survival in late-stage disease models. Our findings potentially translate to a significant survival advantage for human colorectal cancer patients with advanced disease. Our modified extracellular vesicles-based therapy also controls the minimal residual disease that can prevent cancer recurrence functioning as a cancer vaccine. We are seeking out-licensing, co-development, and partnering opportunities.